Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-05EMA Authorised: Rolufta Ellipta (previously Rolufta) (umeclidinium bromide) — GlaxoSmithKline Trading Services Limited
EMA authorised Rolufta Ellipta (umeclidinium bromide) for pulmonary disease including chronic obstructive pulmonary disease (COPD).
-
EMA approval · 2026-07-02EMA Authorised: Trimbow (beclometasone dipropionate;formoterol fumarate dihydrate;glycopyrronium bromide) — Chiesi Farmaceutici S.p.A.
EMA authorised Trimbow (beclometasone dipropionate; formoterol fumarate dihydrate; glycopyrronium bromide) for chronic obstructive pulmonary…
-
EMA approval · 2026-03-17EMA Authorised: Trimbow (beclometasone dipropionate;formoterol fumarate dihydrate;glycopyrronium bromide) — Chiesi Farmaceutici S.p.A.
The European Medicines Agency has authorised Trimbow, a fixed-dose inhaler containing beclometasone dipropionate, formoterol fumarate dihydr…
-
EMA approval · 2026-03-17EMA Authorised: Trydonis (beclometasone dipropionate;formoterol fumarate dihydrate;glycopyrronium) — Chiesi Farmaceutici S.p.A.
EMA authorised Trydonis for chronic obstructive pulmonary disease; a fixed-dose triple inhaler containing beclometasone dipropionate, formot…
-
EMA approval · 2026-02-25EMA Authorised: Daxas (roflumilast) — AstraZeneca AB
The EMA authorised Daxas (roflumilast) for chronic obstructive pulmonary disease; the product is developed by AstraZeneca AB.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-02-23FDA Approved: IPRATROPIUM BROMIDE INHALATION — Original Application (Armstrong Pharmaceuticals, Inc.)
FDA approved Armstrong Pharmaceuticals' ipratropium bromide inhalation under an original ANDA. It is approved for relief of bronchospasm ass…
-
EMA approval · 2026-01-26EMA Authorised: Enurev Breezhaler (glycopyrronium bromide) — Novartis Europharm Ltd
The European Medicines Agency has authorized Enurev Breezhaler, containing glycopyrronium bromide, for the treatment of chronic obstructive …
-
EMA approval · 2026-01-26EMA Authorised: Tovanor Breezhaler (glycopyrronium bromide) — Novartis Europharm Limited
EMA authorised Tovanor Breezhaler, a glycopyrronium bromide inhalation product for chronic obstructive pulmonary disease, with Novartis Euro…
-
EMA approval · 2026-01-26EMA Authorised: Seebri Breezhaler (glycopyrronium bromide) — Novartis Europharm Limited
EMA authorised Seebri Breezhaler, containing glycopyrronium bromide, for the treatment of chronic obstructive pulmonary disease in the Europ…
-
FDA approval · 2026-01-12FDA Approved: FLUTICASONE PROPIONATE AND SALMETEROL — Original Application (Lannett Company, Inc.)
FDA approved a generic version of the fluticasone propionate and salmeterol inhalation product (Lannett) under an original ANDA, for mainten…
-
FDA approval · 2025-12-01FDA Approved: ALBUTEROL SULFATE INHALATION — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal's albuterol sulfate inhalation as a generic inhalation product under ANDA 211600 for relief of bronchospasm in reversibl…
-
EMA approval · 2025-11-18EMA Authorised: Oslif Breezhaler (indacaterol maleate) — Novartis Europharm Limited
The European Medicines Agency authorised Oslif Breezhaler (indacaterol maleate) for chronic obstructive pulmonary disease; decision date 18 …
-
EMA approval · 2025-11-18EMA Authorised: Onbrez Breezhaler (indacaterol maleate) — Novartis Europharm Limited
EU marketing authorization granted for Onbrez Breezhaler (indacaterol maleate) for chronic obstructive pulmonary disease.
-
EMA approval · 2025-11-18EMA Authorised: Hirobriz Breezhaler (indacaterol maleate) — Novartis Europharm Limited
EMA has authorised Hirobriz Breezhaler containing indacaterol maleate for chronic obstructive pulmonary disease (COPD).
-
EMA approval · 2025-09-30EMA Authorised: Riltrava Aerosphere (Budesonide;formoterol fumarate dihydrate;glycopyrronium bromide) — AstraZeneca AB
The European Medicines Agency authorised Riltrava Aerosphere for chronic obstructive pulmonary disease as a triple-inhaler containing budeso…
-
EMA approval · 2025-09-19EMA Authorised: Trixeo Aerosphere (formoterol fumarate dihydrate;glycopyrronium bromide;Budesonide) — AstraZeneca AB
EMA authorised Trixeo Aerosphere, a fixed-dose inhaled triple therapy of budesonide, formoterol fumarate dihydrate and glycopyrronium bromid…
-
EMA approval · 2025-08-27EMA Authorised: Laventair Ellipta (previously Laventair) (umeclidinium bromide;vilanterol) — GlaxoSmithKline Trading Services Limited
EU authorises Laventair Ellipta (umeclidinium bromide and vilanterol) for chronic obstructive pulmonary disease; the product is manufactured…
-
EMA approval · 2025-07-31EMA Authorised: Anoro Ellipta (previously Anoro) (umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited
The EMA authorised Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) for chronic obstructive pulmonary disease, with GlaxoSmit…
-
EMA approval · 2025-07-29EMA Authorised: Eklira Genuair (aclidinium bromide) — Covis Pharma Europe B.V.
The European Medicines Agency authorised Eklira Genuair (aclidinium bromide) for pulmonary disease (COPD) with Covis Pharma Europe B.V. as t…
-
EMA approval · 2025-07-29EMA Authorised: Duaklir Genuair (aclidinium bromide;formoterol fumarate dihydrate) — Covis Pharma Europe B.V.
The European Medicines Agency authorised Duaklir Genuair, a fixed-dose inhaled combination of aclidinium bromide and formoterol fumarate for…
-
EMA approval · 2025-07-25EMA Authorised: Xoterna Breezhaler (indacaterol;glycopyrronium bromide) — Novartis Europharm Limited
EMA authorized Xoterna Breezhaler, a fixed-dose inhalation combination of indacaterol and glycopyrronium bromide, for chronic obstructive pu…
-
EMA approval · 2025-07-25EMA Authorised: Ulunar Breezhaler (glycopyrronium bromide;indacaterol maleate) — Novartis Europharm Limited
The EMA authorised Ulunar Breezhaler, a fixed-dose inhalation combination of glycopyrronium bromide and indacaterol maleate, for chronic obs…
-
EMA approval · 2025-07-25EMA Authorised: Ultibro Breezhaler (indacaterol;glycopyrronium bromide) — Novartis Europharm Limited
EMA authorised Ultibro Breezhaler (indacaterol and glycopyrronium bromide) for chronic obstructive pulmonary disease.
-
EMA approval · 2025-07-22EMA Authorised: Incruse Ellipta (previously Incruse) (umeclidinium bromide) — GlaxoSmithKline Trading Services Limited
The EMA has authorised Incruse Ellipta, a umeclidinium bromide inhaler, for chronic obstructive pulmonary disease.
-
FDA approval · 2025-06-13FDA Approved: THEOPHYLLINE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Theophylline submitted by Chartwell RX, LLC.